Personalised Multi-Cancer Blood Tests Launch in Hong Kong, Urine Screening Due by Year-End
Thestandard · 1 SOURCESabout 4 hours ago2 MIN
Summary
Singapore-based biotechnology company Lucence has introduced its patented multi-cancer early detection blood testing technology at Gleneagles Hospital Hong Kong, marking a significant advancement in personalised cancer screening for Hong Kong patients. The service, called LucenceINSIGHT Me, combines circulating tumour DNA (ctDNA) and circulating tumour RNA (ctRNA) co-testing to improve detection rates for early-stage cancer alterations .
Key Points
- Gleneagles Hospital Hong Kong has become the first private hospital in the city to offer the LucenceINSIGHT Me multi-cancer blood testing service
- The test employs patented technology combining ctDNA and ctRNA co-testing for improved early-stage cancer detection
- The risk-informed screening model allows test panels to be customised based on family history and individual lifestyle factors
- Lucence plans to launch a urine-based test for kidney, bladder and prostate cancer by the end of 2026, with lower costs expected
- The test is recommended for adults aged 40 and above or those with elevated cancer risk
- Dr Min-Han Tan, founding CEO and medical director of Lucence, stated that the future of cancer screening focuses on testing for the right cancers for the right person
- Dr Kenneth Tsang, regional CEO of IHH Healthcare North Asia and CEO of Gleneagles Hospital Hong Kong, emphasised the importance of integrating screening within a complete pathway from result to follow-up to treatment
Why It Matters
This development represents a shift from one-size-fits-all cancer screening toward tailored approaches that consider individual risk profiles, potentially enabling earlier detection and better outcomes for Hong Kong's aging population . The integration of advanced biotechnology into private healthcare may also help alleviate pressure on the city's public healthcare system by providing preventive options that could reduce later-stage cancer treatment costs .
This development represents a shift from one-size-fits-all cancer screening toward tailored approaches that consider individual risk profiles, potentially enabling earlier detection and better outcomes for Hong Kong's aging population . The integration of advanced biotechnology into private healthcare may also help alleviate pressure on the city's public healthcare system by providing preventive options that could reduce later-stage cancer treatment costs .